Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index; 9 of the 30 sources its claims cite were checked for support.

The Human Proteoform Project: Defining the human proteome

Open access
Smith, Lloyd M., Agar, Jeffrey N., Chamot-Rooke, Julia, Danis, Paul O., Ge, Ying, Loo, Joseph A., Paša-Tolić, Ljiljana, Tsybin, Yury O., Kelleher, Neil L., The Consortium for Top-Down Proteomics · 2021 · Science Advances

Abstract

An ambitious initiative is proposed to generate a definitive reference set of human proteoforms.

Overview

CoChat Summary

## TL;DR

The paper is a roadmap/proposal for the Human Proteoform Project, arguing that understanding biology and disease requires a comprehensive reference atlas of human proteoforms, not just genome sequence. It proposes a two-pronged strategy: deep proteoform analysis in medically relevant systems and large-scale technology development for proteoform discovery and characterization.

## Key findings

  • The authors argue that the human proteome should be defined as the set of all proteoforms expressed by an organism, because proteins from a single gene can vary through genetic variation, alternative splicing, and PTMs.
  • They propose an atlas-building strategy centered on two paths: global studies of detectable proteoforms and targeted studies of proteoform families from each human gene.
  • The paper gives explicit scale estimates for the project: assuming 5,000 cell types and a depth of 1 million proteoforms in each, the Human Proteoform Atlas would involve about 5 billion measurements of redundant proteoforms; combined with the gene-based approach, it anticipates about 50 million unique (nonredundant) proteoforms with defined quality metrics.
  • It notes that current bottom-up proteomics remains limited: the aggregated NCI-60 dataset covers only 12% of the whole encoded proteome, only about 5% of genes had >50% sequence coverage of their protein-coding regions, and detection of alternative splice forms remains very limited (<0.1% of putative novel splice junctions in cancer xenografts).

## Methods

  • Not an empirical study; this is a perspective/proposal article laying out a conceptual framework and roadmap for the Human Proteoform Project.
  • The proposed design combines cell-based proteoform discovery across defined human cell types with a gene-based targeted approach using affinity reagents to enrich proteoform families.
  • The main analysis is argumentative and strategic: it synthesizes existing proteomics limitations, compares top-down and bottom-up approaches, and uses rough scale estimates to motivate technology development and atlas construction.

## Limitations

  • The paper states that today’s ability to comprehensively identify proteoforms in complex systems is limited, and that top-down proteomics is powerful but still limited in depth and throughput.
  • It explicitly says the project will necessarily focus on capturing the dominant functional proteoform population rather than rare occurrences.
  • Evident from the text: the paper does not present new experimental data or validate the proposed atlas; its estimates and goals are forward-looking projections rather than results.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1126/sciadv.abk0734

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1. Proteoforms: Distinct protein forms arising from a single gene.
Fig. 1. Proteoforms: Distinct protein forms arising from a single gene.CC BY · PubMed Central
Fig. 2. Proteoforms in human disease. Five important clinical areas of interest are depicted and serve as examples where proteoforms have been identified and linked to the progression of human disease; they are discussed at length in an extended preprint version of this Perspective (32). mAb, monoclonal antibody.
Fig. 2. Proteoforms in human disease. Five important clinical areas of interest are depicted and serve as examples where proteoforms have been identified and linked to the progression of human disease; they are discussed at length in an extended preprint version of this Perspective (32). mAb, monoclonal antibody.CC BY · PubMed Central
Fig. 3. Approach to creating an integrated Human Proteoform Atlas. The upper path illustrates the use of protein affinity reagents to capture proteoform families derived from targeted genes. The lower path illustrates the in-depth analysis of human cell types for proteoform discovery and characterization. Relative abundance refers to the ratio of a given proteoform to the sum of all proteoforms in that family.
Fig. 3. Approach to creating an integrated Human Proteoform Atlas. The upper path illustrates the use of protein affinity reagents to capture proteoform families derived from targeted genes. The lower path illustrates the in-depth analysis of human cell types for proteoform discovery and characterization. Relative abundance refers to the ratio of a given proteoform to the sum of all proteoforms in that family.CC BY · PubMed Central
Fig. 4. The most studied proteins have essential proteoforms that contain common PTMs such as phosphorylation, methylation, acetylation, and other important variations of primary structure such as disulfide bond formation, metal attachment, and proteolytic processing. TNF, tumor necrosis factor; TAU, tubulin-associated unit; HB, hemoglobin subunits (HbA, HbB, etc.); CASP, cysteine-aspartic proteases (Casp1 to Casp9); SOD, superoxide dismutases (SOD-1, SOD-2, and SOD-3); EGFR, estrogen growth factor receptor; CYTC, cytochrome C; TN, troponin (Tn-C, Tn-I, and Tn-T); APOE, apolipoprotein E; CA, carbonic anhydrase; CREB, cyclic adenosine 5′-monophosphate response element–binding protein; TP53, cellular tumor antigen p53. Citations are from the Web of Science Core Collection from 1975 to 2020. Citations per year and a history of research trends have been chronicled for a subset of these proteins (46).
Fig. 4. The most studied proteins have essential proteoforms that contain common PTMs such as phosphorylation, methylation, acetylation, and other important variations of primary structure such as disulfide bond formation, metal attachment, and proteolytic processing. TNF, tumor necrosis factor; TAU, tubulin-associated unit; HB, hemoglobin subunits (HbA, HbB, etc.); CASP, cysteine-aspartic proteases (Casp1 to Casp9); SOD, superoxide dismutases (SOD-1, SOD-2, and SOD-3); EGFR, estrogen growth factor receptor; CYTC, cytochrome C; TN, troponin (Tn-C, Tn-I, and Tn-T); APOE, apolipoprotein E; CA, carbonic anhydrase; CREB, cyclic adenosine 5′-monophosphate response element–binding protein; TP53, cellular tumor antigen p53. Citations are from the Web of Science Core Collection from 1975 to 2020. Citations per year and a history of research trends have been chronicled for a subset of these proteins (46).CC BY · PubMed Central
Fig. 5. Once proteoforms have been identified, affinity reagents and targeted assays will enable emergent strategies to delineate their spatial distribution and temporal dynamics of proteoforms and their PTMs. CyTOF, mass cytometry; CODEX, CO-Detection by indEXing.
Fig. 5. Once proteoforms have been identified, affinity reagents and targeted assays will enable emergent strategies to delineate their spatial distribution and temporal dynamics of proteoforms and their PTMs. CyTOF, mass cytometry; CODEX, CO-Detection by indEXing.CC BY · PubMed Central
Fig. 6. Projected interactions and impact from the Human Proteoform Project.
Fig. 6. Projected interactions and impact from the Human Proteoform Project.CC BY · PubMed Central

Verification

Claims the paper makes

6 Valid · 2 Not valid · 13 Not checked · 14 Own results and interpretations

5 more claims

Create a free account to see all 35 claims and to verify the 21 references still open.

See all claims — free account
  • Probably not a substantial claim. 17
  • It may state two separate claims as one. 12

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 49 references

Cited by

See all 242

Metadata

Authors
Smith, L. M., Agar, J. N., Chamot-Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., Paša-Tolić, L., Tsybin, Y. O., Kelleher, N. L., & The Consortium for Top-Down Proteomics
Affiliations
  • University of Wisconsin–Madison (US)
  • Northeastern University (US)
  • Department of Structural Biology and Chemistry, Institut Pasteur, CNRS, Paris, France.
  • Consortium for Top-Down Proteomics, Cambridge, MA, USA.
  • University of California, Los Angeles (US)
  • Pacific Northwest National Laboratory, Richland, WA, USA.
  • Spectroswiss (Switzerland) (CH)
  • Northwestern University (US)
Corresponding author
Kelleher, Neil L.
Venue
Science Advances
Published
2021-11-12
Volume
7
Issue
46
Pages
eabk0734-eabk0734
ISSN
2375-2548 (ISSN-L)
OpenAlex
W3212853007
Cited by
242
References
49
Citations by year
2026: 43 · 2025: 51 · 2024: 51 · 2023: 52 · 2022: 39 · 2021: 6
FWCI
13.51
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Science Advances (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
  • Zenodo (CERN European Organization for Nuclear Research) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
Funders
  • U.S. Department of Energy (DE-AC05–76RL01830, 76RL01830, AC05-76RL01830, DE-AC05?, DEFC0202ER63421, FC02-02ER63421)
  • Centre National de la Recherche Scientifique
  • National Institutes of Health (DE-FC02-02ER63421, UL1TR001422, HL096971, DE-AC05-76RL01830)
  • Office of Science (02ER63421, DEFC0202ER63421, DE‐AC05‐76 RL01830)
  • National Heart, Lung, and Blood Institute (R01HL096971)
  • National Cancer Institute (UG3CA256959)
  • National Institute of General Medical Sciences (P41GM108569, GM117058, R01GM103479, GM125085, R01GM125085, R01GM117058, R35GM126914)
  • National Center for Advancing Translational Sciences
  • Biological and Environmental Research (DE-AC05-76 RL01830, DE‐FC02‐02ER63421, AC05-76RL01830, 76RL01830)
  • Common Fund
Topics
  • Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced Biosensing Techniques and Applications
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Redox biology and oxidative stress
Keywords
human proteome, proteoforms, post-translational modification, genetic polymorphism, disease research, proteomics technologies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Human Proteoform Project: Defining the human proteome. https://app.cochat.ai/papers/10.1126/sciadv.abk0734
The paper
Smith, L. M., Agar, J. N., Chamot-Rooke, J., Danis, P. O., Ge, Y., Loo, J. A., Paša-Tolić, L., Tsybin, Y. O., Kelleher, N. L., & The Consortium for Top-Down Proteomics. (2021). The Human Proteoform Project: Defining the human proteome. Science Advances. https://doi.org/10.1126/sciadv.abk0734

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.